Coming soon: Updated website and features - Click here for more information

Nyheter ifrån Redeye

BioInvent - Rights issue

Redeye advised, structured and implemented the guarantee consortia in BioInvent´s rights issue announced 14 February 2012 amounting to SEK 105 mn. The rights issue is 100% guaranteed.

The Board of Directors of BioInvent has resolved, subject to the approval by the General Meeting, to conduct a new share issue with preferential rights for the shareholders of the company. The purpose of the rights issue is to strengthen BioInvent's financial position and thereby enable the fulfillment of the company's commercial strategy. Ten existing shares in BioInvent entitle to subscription for one new share. The subscription price is SEK 15.60 per share, corresponding to total issue proceeds of a maximum of approx. SEK 104,8 million, before transaction costs. The subscription period will be from 16 March up to and including 30 March 2012. The Board of Directors has simultaneously resolved to convene an Extraordinary General Meeting to be held on 9 March 2012 for the approval of the rights issue.

BioInvent International AB, listed on the NASDAQ OMX Stockholm, is a research-based pharmaceutical company that focuses on developing antibody drugs. The Company currently has four clinical development projects within the areas of thrombosis, cancer and atherosclerosis. The Company has signed various strategic alliances to strengthen the product pipeline and increase the likelihood of success. These partners include Genentech, Human Genome Sciences, Roche and ThromboGenics.

For more information, contact:
Magnus Vestin, Director, Corporate Finance
+46 70 497 58 82
About Redeye
Redeye AB is a specialist investment banking boutique that focuses on small and mid-cap growth companies in the Nordic region. We focus on the IT, life sciences, media, betting, clean tech and commodities sectors. We provide services within Corporate Broking, Corporate Finance, equity research, investor relations and media services. Our strengths are our award-winning research and analysis department, experienced advisers, a unique investor network, and powerful distribution channel Redeye was founded in 1999 and since 2007 has been subject to the supervision of the Swedish Financial Supervisory Authority.

Fler nyheter ifrån Redeye

Publiceringsdatum Titel
2012-02-21 Capilon - Public offer
2012-02-21 BioInvent - Rights issue
2012-02-06 Vd-byte på Redeye
2012-02-02 Redeye inleder analysbevakning av Caperio Holding
2012-01-23 Redeyes Life Science-favoriter för 2012
2011-11-30 Redeye advising Arctic Gold in SEK 10.5m private placement
2011-11-23 Redeye arranged IT-seminar with 15 presenting companies
2011-11-08 Redeye in cooperation with Nordnet arranged Börsdagarna
2011-10-13 Redeye arranged themed betting event focused on legal risks in the business
2011-10-06 Redeye arranged Exploration & Mining Seminar with 6 presenting companies
2011-07-15 Richard Goldman joins Redeye as Head of Corporate Finance
2011-07-01 Redeye advising Mintage Scientific AB in SEK 12m rights offering
2011-06-01 Redeye assisting in block transaction in Hansa Medical and Genovis
2011-05-26 Redeye in cooperation with Avanza arranged Börsdagarna
2011-05-01 Redeye assisting Moberg Derma in IPO
2011-04-01 Redeye assisting in private placement in Lociloci
2011-04-01 Redeye assisting in private placement in Connected Tables
2011-01-21 Redeyes fem IT-favoriter för 2011
2011-01-01 Redeye advising the divestment of
2011-01-01 Magnus Vestin joins Redeye as Director at Redeye Corporate Finance
2010-12-01 Redeye assisting InDex Pharmaceutical in private placement
2010-11-30 Redeye AB rådgivare åt Farstorp Invest i samband med offentligt bud på Biolin Scientific
2010-11-10 Sveriges första aktieanalys-app för din iPhone
2010-10-31 Samarbetet mellan Redeye och Tanglin upphör